Kinnate Biopharma Inc. (KNTE)

Overview

Kinnate Biopharma Inc. is a forward-thinking clinical-stage oncology company based in the United States, primarily engaged in the pioneering discovery and development of small molecule kinase inhibitors aimed at treating genomically defined cancers. With its inception in 2018, the company has established itself as a significant player in the oncology space. Headquartered in San Francisco, California, Kinnate leverages its expertise in kinase biology and medicinal chemistry to develop targeted therapies that address unmet needs in cancer treatment. Originally a subsidiary of Fount Therapeutics, LLC, Kinnate has now emerged as an independent entity, committed to transforming the landscape of cancer care through innovative therapeutic solutions.

Products and Services

• KIN-2787

  As a cornerstone of Kinnate's product pipeline, KIN-2787 stands out as a potent inhibitor of the rapidly accelerated fibrosarcoma (RAF) family, specifically designed for the treatment of patients suffering from lung cancer, melanoma, and various other solid tumors. This small molecule kinase inhibitor works by targeting the genetic aberrations that drive the growth and spread of tumors, offering a new hope for patients with genomically defined cancers.

• KIN-3248

  Furthering its commitment to innovative cancer solutions, Kinnate is developing KIN-3248, a next-generation small-molecule kinase inhibitor that addresses cancer-associated alterations in the fibroblast growth factor receptors (FGFR2 and FGFR3) genes. This precision-targeted therapy is being crafted to overcome resistance mechanisms and provide effective treatment options for patients with cancers driven by FGFR2 and FGFR3 genetic mutations.

• Cyclin-Dependent Kinase 12 (CDK12) Inhibitor - KIN004 Program

  In its pursuit of groundbreaking treatments, Kinnate is conducting research on a small molecule inhibitor exclusive to Cyclin-Dependent Kinase 12 (CDK12). Positioned within its KIN004 program, this inhibitor is aimed at exploiting specific vulnerabilities in cancer cells, thereby inhibiting their proliferation and survival. Through meticulous research and development, Kinnate seeks to deliver new therapeutics that can challenge the most daunting aspects of cancer treatment.